Importantly, upregulation of AKT3, which is epigenetically regulated by extra terminal domain proteins and bromodomain proteins, has been found to confer AKT inhibitor MK-2206 resistance in breast cancer, providing a rationale for developing future drug therapies targeting AKT3 in order to evade this acquired resistance [367]. This evidence concerns the gene AKT3 and breast carcinoma.